Gyre Therapeutics股价暴跌16%，发行价为2000万美元

• Gyre Therapeutics (NASDAQ:GYRE) priced its previously announced underwritten public offering of ~2.22M shares at a public offering price of $9.00 per share.
• Underwriters have a 30 option to purchase up to an additional 333,333 shares.
• The gross proceeds are expected to be approximately $20.0 million.
• The offering is expected to close on or about May 27, 2025.
• The net proceeds will be used to advance its Phase 2 clinical trial of F351 in metabolic dysfunction-associated steatohepatitis (“MASH”)-associated liver fibrosis in the United States, for research and development, manufacturing and scale-up, as well as for working capital and general corporate purposes.
• The stock price declined 16% on Thursday during after-market hours of trading.

More on Gyre Therapeutics

• Gyre: Intriguing Upcoming Data Catalyst, But I'm Still On Sidelines
• Gyre Therapeutics commences underwritten public offering
• Seeking Alpha’s Quant Rating on Gyre Therapeutics
• Historical earnings data for Gyre Therapeutics
• Financial information for Gyre Therapeutics